Scientists figure out why stress turns your hair gray – Big Think

It's not your imagination, it turns out. Stress can turn a person's hair gray. It's said that if you look at before and after pictures of any eight-year U.S. president the impact of the office on hair color is clear, though in fairness, it may be that candidates dye their hair and then at some point stop doing so. Nonetheless, scientists from Harvard have not only verified the conventional wisdom on our graying noggins, but have also figured out why stress is so brutal to our follicular pigmentation.

The new research from Harvard scientists is published in the journal Nature.

Image source: Ververidis Vasilis/Evan El-Amin/Vacclav/Shutterstock/Big Think

Senior author of the study Ya-Chieh Hsu, professor of Stem Cell and Regenerative Biology at Harvard, explains what prompted her research:

"Everyone has an anecdote to share about how stress affects their body, particularly in their skin and hair the only tissues we can see from the outside. We wanted to understand if this connection is true, and if so, how stress leads to changes in diverse tissues. Hair pigmentation is such an accessible and tractable system to start with and besides, we were genuinely curious to see if stress indeed leads to hair graying."

It turns out that stress activates nerves associated with our basic fight-or-flight system, and these nerves permanently damage pigment-regenerating melanocyte stem cells in hair follicles, causing them to cease production of melanin that normal provides color to hair follicles.

Hsu's team studied the issue using mice, and was somewhat stunned at their findings. "When we started to study this, I expected that stress was bad for the body but the detrimental impact of stress that we discovered was beyond what I imagined," recalls Hsu.

The scientists stressed the mice using a combination of three methods:

Image source: Helga Lei/Shutterstock

Hsu and her colleagues first suspected an immune system reaction was at the root of graying hairs only to discover that mice without immune systems still turned gray in response to stressors. The next suspect was cortisol produced by the adrenal glands however, this proved not to be so. "Stress always elevates levels of the hormone cortisol in the body," says Jsu, "so we thought that cortisol might play a role. But surprisingly, when we removed the adrenal gland from the mice so that they couldn't produce cortisol-like hormones, their hair still turned gray under stress."

Image source: Judy Blomquist/Harvard University

Finally, the researchers investigate the possibility that the system responding to stressors was the mice's sympathetic nervous systems, the part of the nervous system that kicks into action with the fight-or-flight impulse. The sympathetic nervous system is a vast network of nerves that connects, among other places, to hair follicles in the skin. In response to stress, the system sends a rush of the chemical norepinephrine to the follicles' melanocyte stem cell, causing them to quickly burn through and deplete their stores of pigment.

Say Hsu, "After just a few days, all of the pigment-regenerating stem cells were lost. Once they're gone, you can't regenerate pigments anymore. The damage is permanent." Great for survival, not so good for hair color.

Sympathetic system nerves are magenta above. Melanocyte stem cells are yellow.

Image source: Hsu Laboratory, Harvard University

"Acute stress," says lead author of the study Bing Zhang, "particularly the fight-or-flight response, has been traditionally viewed to be beneficial for an animal's survival. But in this case, acute stress causes permanent depletion of stem cells."

The research, done in collaboration with other Harvard researchers, presents a new appreciation of the effect the sympathetic system can have on the body's cells during stress.

One of these collaborators, Harvard immunologist Isaac Chu, notes, "We know that peripheral neurons powerfully regulate organ function, blood vessels, and immunity, but less is known about how they regulate stem cells. With this study, we now know that neurons can control stem cells and their function, and can explain how they interact at the cellular and molecular levels to link stress with hair graying."

Given this finding regarding the direct impact of stress on follicular stem cells, the question of what it else it may affect becomes an obvious one. As Hsu sums it up, "By understanding precisely how stress affects stem cells that regenerate pigment, we've laid the groundwork for understanding how stress affects other tissues and organs in the body."

This importance of the study therefore goes way beyond graying heads. "Understanding how our tissues change under stress is the first critical step," says Hsu, "toward eventual treatment that can halt or revert the detrimental impact of stress. We still have a lot to learn in this area."

Related Articles Around the Web

Continued here:
Scientists figure out why stress turns your hair gray - Big Think

The Asia Pacific cell line development market is expected to reach US$ 2,813.78 Mn in 2027 from US$ 987.48 Mn in 2019 – Yahoo Finance

The market is estimated to grow with a CAGR of 14. 0% from 2020-2027. The growth of the cell line development market is primarily attributed to the increasing foreign direct investments in these countries, highly skilled, efficient, and a large number of human resources, streamlining government policies resulting in high expenditures for the biotechnology sector.

New York, March 19, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Cell Line Development Market to 2027 - Regional Analysis and Forecasts by Type ; By Product ; Application ; and Geography" - https://www.reportlinker.com/p05875826/?utm_source=GNW

In the last few years, stem cell research became a significant field in the Asia Pacific medical sector, experiencing good development vision for the treatment of some challenging diseases.The government of the country organized various awareness programs for stem cell research.

Moreover, the growing number of players operating across the country manufactures products for cell line development. The countries such as Australia, India, and South Korea are estimated to serve various growth opportunities due to the rising development in the biotechnology sector.Moreover, the companies are performing various activities for the cell line development market, for instance, Selexis, Carestream Avacta, JSR Life Sciences. has done recent developments for products.In 2018, the recombinant cell line segment held the most significant market share of the cell line development market, by type.This segment is also anticipated to dominate the market in 2027 owing to its popularity among manufacturers for the production of therapeutic recombinant proteins.

The hybridomas segment is anticipated to witness growth at a significant rate during the forecast period.The Japan cell line development market is dominated by intraoral media and reagent segment in 2019 with a considerable market share, by product.This segment is also predicted to dominate the market in 2027.

Also, media and reagent segment is anticipated to witness growth at a significant rate during the forecast period, owing to the increasing research activities in biotechnology sector.In 2019, the Bioproduction segment held a considerable market of the cell line development market, by the application.This segment is also predicted to dominate the market in 2027 owing to higher demand of biologics.

However, the drug discovery segment is anticipated to witness growth at a significant rate during the forecast period.Some of the major primary and secondary sources for cell line development included in the report are Chinese Academy of Sciences, Council of Scientific and Industrial Research, and others.Read the full report: https://www.reportlinker.com/p05875826/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Link:
The Asia Pacific cell line development market is expected to reach US$ 2,813.78 Mn in 2027 from US$ 987.48 Mn in 2019 - Yahoo Finance

Inside the outbreak: Harnessing high tech – Science & Tech – WORLD News Group

In some Chinese hospitals, robots clean, remove contaminated items, and deliver food and medicine to patients to keep humans from spreading the new coronavirus. The robots can work for up to eight hours after charging for 20 minutes and return to the charging station when their power runs low. Not only are they more sanitary, but they also save time and conserve the protective gear workers must don when they see patients, Luo Xiaodan, deputy director of Guangdong Provincial Peoples Hospital, told China Daily.

No other pandemic fight has had as much assistance from robots, drones, and artificial intelligence as the new coronavirus outbreak. But the extensive use of technology in public health also poses new risks to privacy that could last long after COVID-19 dies out.

Some tech companies are donating their products to help keep the public safe. Dimer UVC Innovations is offering free use of its GermFalcon machine to airlines at select U.S. airports during the outbreak. The robot uses ultraviolet light to kill 99.99 percent of bacteria, viruses, and superbugs on airplanes. Zoom Video Communications said it will make its conferencing program available for free to K-12 schools in Japan, Italy, and the United States, Tech Crunch reported.

Governments and healthcare providers are also investing in new technology as they search for creative ways to fight the pandemic. A Swiss startup company called Calyps supplies French hospitals with artificial intelligence that analyzes weather forecasts, hospital data, public events, and seasonal flu patterns to predict patient flow up to seven days in advance, France 24 reported.

At Beijings Qinghe Railway Station, infrared systems powered by artificial intelligence can check 200 temperatures a minute while people wait for trains without disrupting the flow of traffic, according to MIT Technology Review. Other AI programs can read thousands of CT scans in 20 seconds with 96 percent accuracy, helping doctors diagnose the pneumonia that often accompanies COVID-19.

Drone technology can help deliver medical supplies. Japans Terra Drone transports medical samples and quarantine material between control centers and hospitals. Drones can also patrol public spaces and track quarantine violations.

Other tech companies offer solutions to make social distancing and widespread closures easier to navigate. Baidu in China offers an online doctor consultation service for people with limited access to medical resources or to those who want to see a doctor without risk of exposing themselves or others to illness. The service offers a network of more than 100,000 respiratory specialists and has already handled more than 15 million inquiries, MIT Technology Review reported.

Web giant Alibaba designed an app that Chinese authorities use to track people who visited infected areas or had contact with anyone who tested positive for the coronavirus. Based on that information, the application sends a QR code to the persons phone. If the code is red or yellow, the person cannot access workplaces, residential buildings, or various transit stations. While some people like the ideaone person told France 24 it is reassuringit does have downsides. One man received a red code that blocked him from work for two days even though he had not traveled to an infected area or come near anyone with COVID-19. In a country known for intrusive surveillance, many fear the increased invasion of privacy will desensitize people to a new level of control. Over time we see more and more intrusive use of technology and less ability of people to push back, Maya Wang, senior China researcher for Human Rights Watch, told The Guardian.

Read the original here:
Inside the outbreak: Harnessing high tech - Science & Tech - WORLD News Group

UC San Diego executive David Brenner withdraws bid to become president of University of Central Florida – The San Diego Union-Tribune

Dr. David Brenner, the UC San Diego executive who has presided over the largest expansion of the health sciences and hospitals in the schools history, has withdrawn his bid to become president of the University of Central Florida.

The 67-year-old Brenner withdrew on Wednesday for undisclosed reasons, according to a report in the Orlando Sentinel newspaper.

Given Dr. Brenners success as a world-class innovator, we are disappointed that he chose not to continue in our process, Beverly Seay, chair of UCFs board of trustees, told the paper.

Brenner turned away from a university that, in many ways, is a lot like UCSD.

Both are public research schools that were founded after World War II. UCSD was created in 1960 and UCF arrived three years later. But UCF surpassed UCSD in growth and now has almost 70,000 students, making it one of the three largest universities in the country. UCSD has about 39,000 students, making it one of the largest in California.

UCF is about 35 miles from Cape Canaveral, Fla., and is deeply involved in research that supports NASA and the rest of the American space program.

UCSD is about 11 miles north of downtown San Diego and has evolved into one of the largest health and life sciences research centers in the country. The university brought in more than $1.5 billion in research funding last year, and more than half of it is overseen by Brenner, UCSDs vice chancellor for health sciences.

He led an expansion boom that that included construction of Jacobs Medical Center and the Altman Clinical and Translational Research Institute, where scientists try to speed up the process of turning discoveries into new drugs and therapies.

In 2013, Brenner convinced La Jolla philanthropist Denny Sanford to donate $100 million for a stem cell research facility. Six years later, he got Sanford to donate $100 million for the study of empathy. Last year, Brenner and Chancellor Pradeep Khosla also convinced the UC Board of Regents to approve a new School of Public Health at UCSD.

Here is the original post:
UC San Diego executive David Brenner withdraws bid to become president of University of Central Florida - The San Diego Union-Tribune

Stem Cell Banking Market: Industry Analysis And Detailed Profiles Of Top Industry Players – Jewish Life News

The latest Stem Cell Banking market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thorough analysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. Thhttps://jewishlifenews.com/uncategorized/stem-cell-bankinindustry-players/is study can be described as most wide-ranging documentation that comprises all the aspects of the evolving Stem Cell Banking market.

The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of Stem Cell Banking market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @https://www.theinsightpartners.com/sample/TIPBT00002082/

Stem cell banking or preservation is a combined process of extraction, processing and storage of stem cells, so that they may be used for treatment of various medical conditions in the future, when required. Stem cells have the amazing power to get transformed into any tissue or organ in the body. In recent days, stem cells are used to treat variety of life-threatening diseases such as blood and bone marrow diseases, blood cancers, and immune disorders among others.

The market of stem cell banking is anticipated to grow with a significant rate in the coming years, owing to factors such as, development of novel technologies for stem cell preservation and processing, and storage; growing awareness on the potential of stem cells for various therapeutic conditions. Moreover, increasing investments in stem cell research is also expected to propel the growth of the stem cell banking market across the globe. On other hand rising burden of major diseases and emerging economies are expected to offer significant growth opportunities for the players operating in stem cell banking market.

Key Players

The stem cell banking market report also includes the profiles of key companies engaged with stem cell banking along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years. Some of the key players influencing the market are Cordlife, ViaCord (A Subsidiary of PerkinElmer), Cryo-Save AG, StemCyte India Therapeutics Pvt. Ltd., Cryo-Cell International, Inc., SMART CELLS PLUS, Vita 34, LifeCell, Global Cord Blood Corporation, CBR Systems, Inc.

The research provides answers to the following key questions:

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Stem Cell Banking market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal according to different segments. The report also predicts the influence of different industry aspects on the Stem Cell Banking market segments and regions.

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Interested in purchasing this Report? Click here @https://www.theinsightpartners.com/buy/TIPBT00002082/

Stem Cell Banking Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

See more here:
Stem Cell Banking Market: Industry Analysis And Detailed Profiles Of Top Industry Players - Jewish Life News

Ready To Use Autologous Stem Cell Based Therapies Market size and forecast, 2019-2020 – Packaging News 24

With having published myriads of reports, Autologous Stem Cell Based Therapies Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, Autologous Stem Cell Based Therapies Market Research serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Autologous Stem Cell Based Therapies market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Autologous Stem Cell Based Therapies market.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2278181&source=atm

The Autologous Stem Cell Based Therapies market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

The key players covered in this studyRegeneusMesoblastPluristem Therapeutics IncU.S. STEM CELL, INC.Brainstorm Cell TherapeuticsTigenixMed cell Europe

Market segment by Type, the product can be split intoEmbryonic Stem CellResident Cardiac Stem CellsUmbilical Cord Blood Stem Cells

Market segment by Application, split intoNeurodegenerative DisordersAutoimmune DiseasesCardiovascular Diseases

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Autologous Stem Cell Based Therapies status, future forecast, growth opportunity, key market and key players.To present the Autologous Stem Cell Based Therapies development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Autologous Stem Cell Based Therapies are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2278181&source=atm

What does the Autologous Stem Cell Based Therapies market report contain?

Readers can get the answers of the following questions while going through the Autologous Stem Cell Based Therapies market report:

And many more

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2278181&licType=S&source=atm

For More Information Kindly Contact:

marketresearchhub.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

More here:
Ready To Use Autologous Stem Cell Based Therapies Market size and forecast, 2019-2020 - Packaging News 24

Amniotic Fluid Stem Cell Therapy Market Drivers Analysis by 2025 – 3rd Watch News

Global Amniotic Fluid Stem Cell Therapy Market From PMRs Viewpoint

Decorated with a team of 300+ analysts, PMR Insights serves each and every requirement of the clients while preparing market reports. With digital intelligence solutions, we offer actionable insights to our customers that help them in overcoming market challenges. Our dedicated team of professionals perform an extensive survey for gathering accurate information associated with the market.

PMR, in its latest business report elaborates the current situation of the global Amniotic Fluid Stem Cell Therapy market in terms of volume (x units), value (Mn/Bn USD), production, and consumption. The report scrutinizes the market into various segments, end uses, regions and players on the basis of demand pattern, and future prospect.

In this Amniotic Fluid Stem Cell Therapy market study, the following years are considered to project the market footprint:

Request Sample Report @ https://www.persistencemarketresearch.co/samples/23101

On the basis of product type, the global Amniotic Fluid Stem Cell Therapy market report covers the key segments,

key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/23101

The Amniotic Fluid Stem Cell Therapy market research addresses the following queries:

After reading the Amniotic Fluid Stem Cell Therapy market report, readers can

Amniotic Fluid Stem Cell Therapy market players Player 1, Player 2, Player 3, and Player 4, among others represent the global Amniotic Fluid Stem Cell Therapy market. The market study depicts an extensive analysis of all the players running in the Amniotic Fluid Stem Cell Therapy market report based on distribution channels, local network, innovative launches, industrial penetration, production methods, and revenue generation. Further, the market strategies, and mergers & acquisitions associated with the players are enclosed in the Amniotic Fluid Stem Cell Therapy market report.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/23101

About us:

PMR is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Excerpt from:
Amniotic Fluid Stem Cell Therapy Market Drivers Analysis by 2025 - 3rd Watch News

Government of Canada invests in regenerative medicine research to support Canadians health #46662 – New Kerala

Since first discovering the existence of stem cells, Canadian researchers have been world leaders in this cutting-edge field, working to bring this technology from the lab and into hospitals to improve and save countless lives.

Today, on behalf of Minister Navdeep Bains, William Amos, Parliamentary Secretary to the Minister of Innovation, Science and Industry (Science), announced an investment of $6.9 million through the Stem Cell Network's competitive research funding program, which supports some of the country's most promising stem cell research.

The funding will support nine translational projects and four clinical trials across the country aimed at bringing new therapies to the clinic and fostering continued growth in Canada's regenerative medicine sector. This includes supporting 200 researchers and trainees at 27 Canadian research institutions in Alberta, British Columbia, Quebec and Ontario, as well as direct partnerships with several emerging biotechnology companies.

Parliamentary Secretary Amos made the announcement at the Maisonneuve-Rosemont Hospital, home to two of the projects announced today. One is a clinical trial that is testing a promising new protocol to make blood stem cell transplants available to more patients with severe leukemia, and the other is a biotechnology partnership that is advancing a stem cell-based approach to vision loss.

Quotes

Stem cell and regenerative medicine are a made-in-Canada success story, and the kind of modern, high-risk, high-reward research that drives innovation and benefits all of us. The Government of Canada is proud to invest in our world-class researchers and scientists that are saving the lives of Canadians and countless others around the world.- William Amos, Parliamentary Secretary to the Minister of Innovation, Science and Industry (Science)

When we invest in science, we invest in better, healthier lives for everyone. Our government's support will help Canadian researchers further their ground-breaking work to tackle some of the most serious illnesses we face today. Congratulations to all of the recipients, and thank you for your work to keep Canada on the cutting edge of discovery and innovation.- The Honourable Navdeep Bains, Minister of Innovation, Science, and Industry

These projects reflect the strength of Canada's stem cell research sector and its collaborative community. Through the efforts of this community, the Stem Cell Network is closer to realizing its goal of translating stem cell-based therapies from bench to bedside for the benefit of Canadians.- Dr. Michael Rudnicki, O.C., Scientific Director & CEO, Stem Cell Network

Nous sommes tres fiers de recevoir ce financement qui confirme l'excellence et la reconnaissance de l'Hopital Maisonneuve-Rosemont comme etant le plus important pole de recherche au Quebec et l'un des plus developpes au Canada en therapie cellulaire et ce, dans les domaines de l'hematologie-oncologie et de l'ophtalmologie. Les progres des dernieres annees dans ces domaines sont porteurs d'espoir pour les personnes touchees par le cancer et les maladies oculaires. C'est notamment grace au soutien financier du Reseau de cellules souches que nos chercheurs continuent d'avoir les leviers necessaires pour faire avancer les connaissances et les traitements novateurs dans ces domaines, au grand benefice de tous. - Sylvain Lemieux, president-directeur general du CIUSSS de l'Est-de-l'le-de-Montreal

Quick facts

The investment made today includes $2.6 million to fund four clinical trials, three of which are based in Quebec and are being led by women researchers.Today's funding is matched with partner support valued at more than $11 million.The disease areas targeted by these projects include severe blood disorders, vision loss, type 1 diabetes, muscular dystrophy and heart, lung and liver diseases.The global regenerative medicine market is estimated to grow to more than $81 billion by 2023.

Here is the original post:
Government of Canada invests in regenerative medicine research to support Canadians health #46662 - New Kerala

A history of soap: How it began and how it fights coronavirus – The Independent

It probably began with an accident thousands of years ago. According to one legend, rain washed the fat and ash from frequent animal sacrifices into a nearby river, where they formed a lather with a remarkable ability to clean skin and clothes. Perhaps the inspiration had a vegetal origin in the frothy solutions produced by boiling or mashing certain plants. However it happened, the ancient discovery of soap altered human history. Although our ancestors could not have foreseen it, soap would ultimately become one of our most effective defences against invisible pathogens.

People typically think of soap as gentle and soothing, but from the perspective of microorganisms, it is often extremely destructive. A drop of ordinary soap diluted in water is sufficient to rupture and kill many types of bacteria and viruses, including the new coronavirus that is currently circling the globe. The secret to soaps impressive might is its hybrid structure.

Soap is made of pin-shaped molecules, each of which has a hydrophilic head it readily bonds with water and a hydrophobic tail, which shuns water and prefers to link up with oils and fats. These molecules, when suspended in water, alternately float about as solitary units, interact with other molecules in the solution and assemble themselves into little bubbles called micelles, with heads pointing outward and tails tucked inside.

Sharing the full story, not just the headlines

Some bacteria and viruses have lipid membranes that resemble double-layered micelles with two bands of hydrophobic tails sandwiched between two rings of hydrophilic heads. These membranes are studded with important proteins that allow viruses to infect cells and perform vital tasks that keep bacteria alive. Pathogens wrapped in lipid membranes include coronaviruses, HIV, the viruses that cause hepatitis B and C, herpes, Ebola, Zika, dengue, and numerous bacteria that attack the intestines and respiratory tract.

When you wash your hands with soap and water, you surround any microorganisms on your skin with soap molecules. The hydrophobic tails of the free-floating soap molecules attempt to evade water; in the process, they wedge themselves into the lipid envelopes of certain microbes and viruses, prying them apart.

They act like crowbars and destabilise the whole system, says Professor Pall Thordarson, acting head of chemistry at the University of New South Wales. Essential proteins spill from the ruptured membranes into the surrounding water, killing the bacteria and rendering the viruses useless.

In tandem, some soap molecules disrupt the chemical bonds that allow bacteria, viruses and grime to stick to surfaces, lifting them off the skin. Micelles can also form around particles of dirt and fragments of viruses and bacteria, suspending them in floating cages. When you rinse your hands, all the microorganisms that have been damaged, trapped and killed by soap molecules are washed away.

On the whole, hand sanitisers are not as reliable as soap. Sanitisers with at least 60 per centethanol do act similarly, defeating bacteria and viruses by destabilising their lipid membranes. But they cannot easily remove microorganisms from the skin. There are also viruses that do not depend on lipid membranes to infect cells, as well as bacteria that protect their delicate membranes with sturdy shields of protein and sugar. Examples include bacteria that can cause meningitis, pneumonia, diarrhoea and skin infections, as well as the hepatitis A virus, poliovirus, rhinoviruses and adenoviruses (frequent causes of the common cold).

These more resilient microbes are generally less susceptible to the chemical onslaught of ethanol and soap. But vigorous scrubbing with soap and water can still expunge these microbes from the skin, which is partly why hand-washing is more effective than sanitiser. Alcohol-based sanitiser is a good back-up when soap and water are not accessible.

In an age of robotic surgery and gene therapy, it is all the more wondrous that a bit of soap in water, an ancient and fundamentally unaltered recipe, remains one of our most valuable medical interventions. Throughout the course of a day, we pick up all sorts of viruses and microorganisms from the objects and people in the environment. When we absentmindedly touch our eyes, nose and mouth a habit, one study suggests, that recurs as often as every two and a halfminutes we offer potentially dangerous microbes a portal to our internal organs.

No hype, just the advice and analysis you need

As a foundation of everyday hygiene, hand-washing was broadly adopted relatively recently. In the 1840s DrIgnaz Semmelweis, a Hungarian physician, discovered that if doctors washed their hands, far fewer women died after childbirth. At the time, microbes were not widely recognised as vectors of disease, and many doctors ridiculed the notion that a lack of personal cleanliness could be responsible for their patients deaths. Ostracised by his colleagues, Semmelweis was eventually committed to an asylum, where he was severely beaten by guards and died from infected wounds.

Florence Nightingale, the English nurse and statistician, also promoted hand-washing in the mid-1800s, but it was not until the 1980s that the US Centres for Disease Control and Prevention issued the worlds first nationally endorsed hand-hygiene guidelines.

Washing with soap and water is one of the key public health practices that can significantly slow the rate of a pandemic and limit the number of infections, preventing a disastrous overburdening of hospitals and clinics. But the technique works only if everyone washes their hands frequently and thoroughly: work up a good lather, scrub your palms and the back of your hands, interlace your fingers, rub your fingertips against your palms, and twist a soapy fist around your thumbs.

Or as the Canadian health officer Bonnie Henry said recently:Wash your hands like youve been chopping jalapenos and you need to change your contacts. Even people who are relatively young and healthy should regularly wash their hands, especially during a pandemic, because they can spread the disease to those who are more vulnerable.

Soap is more than a personal protectant; when used properly, it becomes part of a communal safety net. At the molecular level, soap works by breaking things apart, but at the level of society, it helps hold everything together. Remember this the next time you have the impulse to bypass the sink: other peoples lives are in your hands.

New York Times

More:
A history of soap: How it began and how it fights coronavirus - The Independent

Where We’re at with Vaccines and Treatments for COVID-19 – Healthline

With COVID-19 cases worldwide passing the 200,000 mark and continuing to grow, scientists are pushing forward with efforts to develop vaccines and treatments to slow the pandemic and lessen its damage.

Some of the earliest treatments will likely be drugs that are already approved for other conditions or have been tested on other viruses.

People are looking into whether existing antivirals might work or whether new drugs could be developed to try to tackle the virus, said Dr. Bruce Y. Lee, a professor of health policy and management at City University of New York.

Still, theres only so much that vaccine and drug development can be sped up, even with improvements in genetic sequencing and other technologies.

Even though technological advances allow us to do certain things more quickly, Lee told Healthline, we still have to rely on social distancing, contact tracing, self-isolation, and other measures.

Heres a rundown of the latest COVID-19 vaccine and drug developments.

Several companies are developing or testing antivirals against the virus that causes COVID-19.

Antivirals target the virus in people who already have an infection. They work in different ways, sometimes preventing the virus from replicating, other times blocking it from infecting cells.

Lee says antivirals work better if you administer them sooner, before the virus has a chance to multiply significantly.

And also before the virus has caused significant damage to the body, such as to the lungs or other tissues.

Dr. Robert Amler, dean of the School of Health Sciences and Practice at New York Medical College and former chief medical officer at the Centers for Disease Control and Prevention (CDC), says both antivirals and vaccines will be valuable tools in combating COVID-19.

However, he told Healthline that antivirals are likely to be developed and approved before a vaccine, which typically takes longer.

Drug development is sometimes described as a pipeline with compounds moving from early laboratory development to laboratory and animal testing to clinical trials in people.

It can take a decade or more for a new compound to go from initial discovery to the marketplace. Many compounds never even make it that far.

Thats why antivirals being eyed as treatments for COVID-19 are drugs that already exist. They include:

Scientists are also looking at other ways to target the virus or treat the complications of COVID-19, such as:

While a lot of the focus is on developing new treatments for COVID-19, improvements in how doctors care for patients using existing technology are also crucial.

The things that we have to worry about with the novel coronavirus is that it can cause pneumonia and acute respiratory distress syndrome, Lee said. There are ways of treating those things that can reduce the effects, so doctors are trying to use those as well.

No company has offered a timeline for when its drug might be used more widely to treat COVID-19. This isnt an easy thing to estimate.

After laboratory and animal testing, drugs have to pass through several clinical trial stages before they can be approved for widespread use in people.

Its also difficult to speed things up, because scientists have to enroll enough people in each stage to have useful results. They also have to wait long enough to see whether there are harmful side effects of the drug.

However, drugs can sometimes be given to people outside a clinical trial through the Food and Drug Administrations compassionate use program. For this to happen, people must have an immediately life-threatening condition or serious disease or condition.

Doctors at the University of California, Davis were able to secure this type of approval for a woman with severe COVID-19 to receive remdesivir. They report that shes now doing well.

Many will take this as a sign that the drug works. But because the drug was given outside of a clinical trial to just one person, its not possible to know for certain. Also, other people may not have the same response to the drug.

A vaccine is designed to protect people before theyre exposed to a virus in this case, SARS-CoV-2, the virus that causes COVID-19.

A vaccine basically trains the immune system to recognize and attack the virus when it encounters it.

Vaccines protect both the person whos vaccinated and the community. People who are vaccinated cant become infected with a virus, which means they cant pass it to others. This is known as herd immunity.

Many groups are working on potential vaccines for SARS-CoV-2, with several backed by the nonprofit Coalition for Epidemic Preparedness Innovations (CEPI).

Several of these groups started their work shortly after Chinese scientists shared the genetic sequence of the virus. These include:

Advances in genetic sequencing and other technological developments have sped up some of the earlier laboratory work for vaccine development.

However, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters last week that a vaccine wont be available for widespread use for at least another 12 to 18 months.

This is the timeline to complete the phase III clinical studies. Theres no guarantee that the vaccine candidates will work.

Theres a lot of uncertainty with vaccine development, Lee said. Naturally, you have to make sure the vaccine is safe. But you also have to make sure the vaccine will elicit enough of an immune response.

Like drugs, potential vaccines have to pass through the same clinical trial stages. This is especially important when it comes to safety, even during a pandemic.

The publics willingness to back quarantines and other public-health measures to slow spread tends to correlate with how much people trust the governments health advice, Shibo Jiang, a virologist at Fudan University in China, wrote in the journal Nature.

A rush into potentially risky vaccines and therapies will betray that trust and discourage work to develop better assessments, he said.

Read the rest here:
Where We're at with Vaccines and Treatments for COVID-19 - Healthline